AIFM2 and cancer: This suggests the existence of a novel ferroptosis inhibitory pathway and that inhibition of FSP1 may render cancer patients more sensitive to ferroptosis-inducing chemotherapeutic agents, thereby affecting cancer progression (Bersuker et al., 2019).